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Abstract
Introduction: Cannabinoids have shown to reduce joint damage in animal models of arthritis and reduce ma-
trix metalloproteinase expression in primary human osteoarthritic (OA) chondrocytes. The actions of cannabi-
noids are mediated by a number of receptors, including cannabinoid receptors 1 and 2 (CB1 and CB2), G-
protein-coupled receptors 55 and 18 (GPR55 and GPR18), transient receptor potential vanilloid-1 (TRPV1), and
peroxisome proliferator-activated receptors alpha and gamma (PPARa and PPARc). However, to date very few
studies have investigated the expression and localization of these receptors in human chondrocytes, and expres-
sion during degeneration, and thus their potential in clinical applications is unknown.
Methods: Human articular cartilage from patients with symptomatic OA was graded histologically and the ex-
pression and localization of cannabinoid receptors within OA cartilage and underlying bone were determined
immunohistochemically. Expression levels across regions of cartilage and changes with degeneration were
investigated.
Results: Expression of all the cannabinoid receptors investigated was observed with no change with grade of
degeneration seen in the expression of CB1, CB2, GPR55, PPARa, and PPARc. Conversely, the number of chon-
drocytes within the deep zone of cartilage displaying immunopositivity for GPR18 and TRPV1 was signiﬁcantly
decreased in degenerate cartilage. Receptor expression was higher in chondrocytes than in osteocytes in the
underlying bone.
Conclusions: Chondrocytes from OA joints were shown to express a wide range of cannabinoid receptors even
in degenerate tissues, demonstrating that these cells could respond to cannabinoids. Cannabinoids designed to
bind to receptors inhibiting the catabolic and pain pathways within the arthritic joint, while avoiding psychoac-
tive effects, could provide potential arthritis therapies.
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Introduction
A key feature of osteoarthritis (OA) is the loss of articular
cartilage.1 Cartilage breakdown is mediated by complex
interactions of proinﬂammatory cytokines such as inter-
leukin 1 (IL-1) and proteases, including matrix metallo-
proteinases (MMPs).2 This results in a shift in the
equilibrium between anabolic and catabolic processes
that maintain the extracellular matrix of predominantly
collagen and proteoglycan under normal physiological
conditions, resulting in cartilage breakdown.
Cannabinoids were originally derived from the can-
nabis plant, Cannabis sativa, which has been used me-
dicinally and recreationally for many years because
of its anti-inﬂammatory, analgesic, and psychoactive
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properties.3 They also include synthetic cannabinoids,
such as WIN-55, 212-2 mesylate (WIN-55), and endog-
enous cannabinoids, (the endocannabinoids), such as
anandamide (arachidonoylethanolamide [AEA]). Can-
nabinoids have been studied in animal models of arthritis
and have been shown to reduce joint damage and have
anti-inﬂammatory effects. Evidence suggests that activa-
tion of cannabinoid receptors may be of therapeutic
value in the treatment of arthritis,4–8 and we have previ-
ously shown that synthetic cannabinoid WIN-55 reduces
the expression of MMP-3 and13 in OA chondrocytes.9
Cannabinoids produce their effects by binding to
and activating cannabinoid receptors.10 Cannabinoid
receptor 1 (CB1) and cannabinoid receptor 2 (CB2)
were originally identiﬁed as the ﬁrst two classical can-
nabinoid receptors.11,12 It is now apparent that not all
cannabinoid actions are mediated by CB1 and CB2.10
Other receptors including peroxisome proliferator-
activated receptors alpha and gamma (PPARa and
PPARc), G-protein-coupled receptor 55 (GPR55), G-
protein-coupled receptor 18 (GPR18), and transient re-
ceptor potential vanilloid 1 (TRPV1) have been identi-
ﬁed as cannabinoid receptors.13–18
The cannabinoid system has been identiﬁed in dif-
ferent cell types of the joint involved in OA and rheu-
matoid arthritis (RA), including bone cells, synovial
cells, and chondrocytes.19–38 CB1 and CB2 receptors
are expressed in bovine and human chondrocyte cul-
tures, human synovial tissue, and human ﬁbroblast-
like synoviocyte cultures.19,20,30,39 Moreover, studies
using the destabilized medial meniscus (DMM) model
of OA have shown that CB2-deﬁcient mice experienced
more severe OA than wild-type (WT) OA mice and
showed increased susceptibility to age-related OA.8
Selective CB2 agonist, HU308, also reduced the severity
of OA in WT control mice but not in CB2-deﬁcient
mice.8 The cannabinoid system in joint cells is, there-
fore, a potential target in the treatment of arthritis.
The PPAR nuclear receptors family has been shown to
bind a number of different cannabinoid ligands and is
thought to have anti-inﬂammatory properties mediated
primarily by PPARc activation.13 These receptors are
expressed at the mRNA and protein levels in rat growth
plate chondrocyte cultures, human cartilage, and isolated
chondrocytes.21–24,26,27 PPAR activation by both canna-
binoid and noncannabinoid ligands displays chondro-
protective activities in both OA and RA.13,21,27,38,40–42
PPARc protein expression has been shown to be down
regulated in human OA cartilage tissue, suggesting that
it may be involved in OA pathogenesis.22
PPARc mRNA expression is down regulated in
human OA chondrocytes treated with IL-1, and both
PPARc and PPARa ligands also inhibited IL-1-induced
MMP and nitric oxide production in human chondro-
cytes, suggesting that these receptors may play an im-
portant role in IL-1-mediated cartilage breakdown
and inﬂammation in arthritis.21,22,24,27 In addition,
PPARc cartilage-speciﬁc knockout (KO) mice exhibit
spontaneous OA, and mice with inducible cartilage-
speciﬁc PPARc KO, subjected to the DMM model of
OA, experienced more rapid development of OA
than control mice.43,44
GPR55 is activated by a number of exogenous and
endogenous cannabinoids.14,15,45 GPR55 is expressed
in both normal and OA human chondrocytes at the
protein level,19 and abnormal cannabinoid O-1602 was
shown to reduce inﬂammatory pain in a rat model of ar-
thritis, which was thought to be mediated by GPR55.46
McHugh et al.16 reported that phytocannabinoid D9-
tetrahydrocannabinol and endogenous cannabinoid
AEA are ligands of GPR18, suggesting that GPR18
may also act as a cannabinoid receptor; however,
GPR18 is yet to be identiﬁed in articular cartilage.16
Cannabinoid receptor TRPV1 is expressed by human
OA chondrocytes and human OA and RA synovial ﬁ-
broblasts.29,32 TRPV1 acts as a receptor for the endog-
enous cannabinoid AEA and has also been shown to
bind the phytocannabinoid: cannabidiol (CBD).17,18
CBD has anti-inﬂammatory and hypoalgesic effects in
a rat model of acute inﬂammation, through TRPV1
activation.47,48
Although previous studies have shown that cannabi-
noids display chondroprotective properties, the expres-
sion of cannabinoid receptors within OA cartilage is
poorly deﬁned. This study aimed to identify and quan-
tify the expression levels of CB1, CB2, GPR55, GPR18,
TRPV1, PPARa, and PPARc in OA cartilage and the
underlying bone. Subchondral bone was investigated
to determine whether potential chondroprotective ef-
fects of cannabinoids may be mediated by receptors
on osteocytes and/or chondrocytes. Cannabinoids have
been demonstrated to have effects on bone metabo-
lism.49 Immunohistochemistry was used to determine
receptor localization and whether expression levels
altered during degeneration.
Materials and Methods
Articular cartilage tissue
Articular cartilage (Table 1) was obtained under the
ethics committee approval held by the Shefﬁeld
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Musculoskeletal Biobank (STH1606, SMB002). All pa-
tients provided written, informed consent before par-
ticipation. Cartilage blocks were taken from waste
tissue within each anatomic compartment of the knee
(medial and lateral tibio-femoral and patello-femoral
compartments) during total knee replacement for OA.
Histology
Cartilage tissue was ﬁxed in 10% v/v formalin in
phosphate-buffered saline (Sigma-Aldrich) followed
by decalciﬁcation (Leica). Graded solutions of indus-
trial methylated spirits (IMS; Fisher) were used to de-
hydrate samples followed by clearing in Sub-X
(Leica). Samples were embedded in parafﬁn wax and
4 lm sections were mounted on slides. Sections were
dewaxed in Sub-X, rehydrated in IMS, washed in dis-
tilled water, stained in 1% w/v Alcian blue/glacial acetic
acid (pH 2.4) for 15min, counter stained in 1% w/v
aqueous neutral red for 1min, or stained with Masson
trichrome (Leica) according to the manufacturer’s in-
structions. Sections were dehydrated and mounted.
Cartilage tissue was graded using the Mankin scores
(0–14) with additional scores for abnormal features
(0–4) and cartilage thickness (0–4) being based on
the OARSI scoring system (Fig. 1 and Table 2).50,51
The total scores were used to determine the overall
grade of the cartilage as nondegenerate (scores 0–6),
low grade degenerate (scores 7–12), intermediate de-
generate (scores 13–17), and severe degenerate (scores
18–22; Table 1).
Immunohistochemistry
Immunohistochemistry was used to detect the expres-
sion and localization of cannabinoid receptors present
in 38 articular cartilage samples, representing a range of
degeneration stages (Table 1). Tissue sections were dew-
axed in Sub-X (Leica) and rehydrated in IMS; before
endogenous peroxide blockade, enzymatic antigen re-
trieval was performed for 30min at 37C in 0.01% w/v
chymotrypsin (Sigma), 0.1% w/v CaCl2 in Tris buffered
saline (TBS), and samples were blocked in 25% v/v goat
serum/1% w/v BSA in TBS for 1 h at room temperature
(Abcam). Samples were incubated overnight at 4C with
rabbit polyclonal antibodies (Abcam) against CB1 (1:100)
(ab23703), CB2 (1:50)(ab3561), PPARa (1:250)(ab8934),
PPARc (1:50)(ab19481), and TRPV1 (1:1000)(ab63083),
and rabbit polyclonal antibodies from Acris (Acris
GmbH) against GPR55 (1:100)(SP4239P) and GRP18
(1:200)(AP06930PU). IgG controls (abcam) were per-
formed for each primary antibody at equivalent IgG con-
centrations. Samples were washed in TBS and incubated
with biotinylated goat antirabbit secondary antibody
(1:300, Abcam) for 30min before detection by the forma-
tion of horseradish peroxidase-streptavidin-biotin com-
plexes (Vector Laboratories) with 3,3¢-diaminobenzidine
tetrahydrochloride as a substrate (Sigma-Aldrich). Sam-
ples were counterstained in hematoxylin (Leica Micro-
systems), dehydrated, and mounted in pertex before
microscopy.
Microscopic analysis
All slides were examined with an Olympus BX51 mi-
croscope and images were captured by a digital camera
and Capture Pro OEM v8.0 software (Media Cyber-
netics). Histological sections were analyzed, features
noted, and images were captured to document their
histological appearance. Grading was performed by
two independent researchers (S.L.D. and C.L.L.M.)
Table 1. Human Cartilage Samples, Macroscopic
and Microscopic Grades of Degeneration
Sample Age Macroscopic grade Microscopic grade
1 82 0 2.5
2 60 0 3
3 65 1 3
4 72 0 3.5
5 72 2–3 4
6 67 3 4
7 73 0 5
8 72 2 5
9 57 0 5
10 72 1 5
11 73 3 8
12 81 1 8.5
13 72 2 8.5
14 65 3 9
15 57 1 9
16 57 0 9.5
17 83 2 10
18 82 2 10
19 67 1 11
20 67 3 13.5
21 81 3 13.5
22 89 2 14.5
23 57 3 14.5
24 72 2 14.5
25 72 3 14.5
26 79 4 15
27 57 2 16
28 83 2 16.5
29 60 3 17.5
30 57 2 17.5
31 73 4 19.5
32 72 4 19.5
33 74 3 19.5
34 67 4 20.5
35 72 4 21
36 74 3 21.5
37 82 4 21.5
38 72 4 22
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and the grades were averaged. For immunochemical
analysis of tissue sections, a total of 200 chondrocytes
were counted in each section in each zone of the carti-
lage where present (superﬁcial, middle, and deep zone,
clusters and osteocytes; please note degenerate cartilage
does not have surface zones) and determined whether
immunopositive or immunonegative. The number of
immunopositive cells was expressed as a percentage
of the total count within each region. Patient samples
were grouped based on histological grades (nondegen-
erate [scores 0–6], low grade degenerate [scores 7–12],
intermediate degenerate [scores 13–17], and severe de-
generate [scores 18–22]; Table 1).
Statistical analysis
The percentage of immunopositive cells for cannabi-
noid receptors was compared between each cartilage
zone using the nonparametric Kruskall–Wallis with
a Conover–Inman post hoc test. Nonparametric lin-
ear regression was used to determine the relationship
between the grade of degeneration compared to immu-
nopositivity within each of the cartilage zones. All sta-
tistical analyses were performed using StatsDirect.
Results
Cannabinoid receptor expression in OA cartilage
and bone
CB1, CB2, GPR55, GPR18, TRPV1, PPARa, and PPARc
immunopositivity was observed in single chondrocytes,
chondrocyte clusters, and in osteocytes in the underlying
bone (Fig. 2). CB1, CB2, TRPV1, and PPARa expression
levels were signiﬁcantly higher in the chondrocytes pres-
ent in the superﬁcial zone, middle zone, deep zone, and
clusters than staining in osteocytes (all p values are less
than 0.01, see ﬁgure for speciﬁc p values; Fig. 3A, B, E
and F). GPR55 expression was signiﬁcantly higher in
the middle zone, deep zone, and clusters than staining
in the osteocytes ( p< 0.001; Fig. 3C). Increased expres-
sion of GPR18 was detected in the middle ( p < 0.001)
and deep zone ( p < 0.05) compared to the superﬁcial
zone of the cartilage (Fig. 3D). Expression of PPARc
was signiﬁcantly higher in the superﬁcial and middle
zones than in the osteocytes ( p < 0.001; Fig. 3G).
There was no signiﬁcant difference between CB1,
CB2, GPR55, GPR18, TRPV1, PPARa, and PPARc ex-
pression in chondrocytes in the superﬁcial zone, mid-
dle zone, or those present in clusters between grades
FIG. 1. Histological features used to inform grading of degeneration. Representative images shown to
highlight key features seen in the different grades of degeneration, which link to the histological grading
system used (Table 2). A–D demonstrate key features of each grade of degeneration.
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of degeneration (data not shown). There was no signif-
icant difference in CB1, CB2, GPR55, PPARa, and
PPARc expression between grades of degeneration in
the deep zone of the cartilage (Fig. 4A–C, F and G);
however, a signiﬁcant decrease in GPR18 and TRPV1
expression in the severe degenerate samples compared
to the low degenerate samples within the deep zone of
the cartilage was seen ( p< 0.05; Fig. 4D,E). Regression
analysis of GPR18 immunopositivity and the histolog-
ical grade of degeneration conﬁrmed that there was a
signiﬁcant negative correlation between GPR18 expres-
sion and grade of degeneration in the chondrocytes in
the deep zone of the cartilage ( p = 0.0268; Fig. 4H),
which was not the case for TRPV1 ( p> 0.05; data not
shown).
Osteocyte immunopositivity for CB1, CB2, GPR55,
GPR18, TRPV1, and PPARa was not affected by
grade of degeneration (Fig. 5A–F). However, PPARc
expression was signiﬁcantly decreased in the osteocytes
in severe degenerate samples compared to nondegener-
ate samples ( p< 0.05; Fig. 5G), with an inverse correla-
tion observed between PPARc immunopositivity and
grade of degeneration ( p = 0.0229; Fig. 5H).
Discussion
This study demonstrated that both chondrocytes and
osteocytes in the underlying bone express CB1, CB2,
GPR55, GPR18, TRPV1, PPARa, and PPARc recep-
tors, demonstrating that these cells have the potential
to respond to endocannabinoids expressed within the
joint and also synthetic cannabinoids. These receptors
may be potential targets for arthritis therapies.52 The
expression of the majority of the receptors was simi-
lar across all zones of cartilage and within single cells
to the same extent as clusters. However, higher recep-
tor expression was seen in chondrocytes than in os-
teocytes, suggesting that chondrocytes may be more
responsive to cannabinoids than to osteocytes; there-
fore, chondroprotective effects of cannabinoids are
more likely to be mediated by chondrocytes than by os-
teocytes. In relation to this, CB2 receptors appeared to
have minimal effects on bone in DMM-induced OA as
CB2-deﬁcient mice showed little or no changes in sub-
chondral bone.8 To date, few studies have investigated
the expression of cannabinoid receptors within the
joint and none have investigated expression across
the zones of cartilage, an important ﬁnding as the
Table 2. Histological Grading of Cartilage Sections
Item Classification Score
Structure (H&E/MT) Normal 0
Superficial fibrillation surface irregularities 1
Pannus and surface irregularities 2
Clefts to transitional zone 3
Clefts to radial zone 4
Clefts to calcified zone 5
Complete disorganization 6
Cells (H&E/MT) Normal 0
Diffuse hypercellularity (<25%) 1
Clusters (25–75%) 2
Hypocellularity (>75%) 3
Proteoglycan content (Alcian Blue) Normal 0
Slight reduction (surface zone loss) 1
Moderate reduction (upper 1/3 loss) 2
Severe reduction (into upper 2/3 deep zone) 3
No staining present or very limited in bottom 1/3 4
Tidemark integrity (H&E/MT) Intact 0
Crossed by blood vessels 1
Abnormal features (H&E/MT) None 0
Denudation: surface sclerotic bone or reparative
tissue including fibrocartilage microfractures
with limited repair to bone surface
2
Deformation: bone remodeling (more than osteophyte
formation) includes microfracture with fibrocartilaginous
and osseous repair extending above previous surface
4
Cartilage thickness (H&E/MT) Normal smooth articulating surface 0
Thinning of superficial zone 1
Thinning into middle zone (>25% surface area) 2
Thinning into deep zone (>25% surface area) 3
Areas where bone exposed (>25% surface area) 4
H&E, hematoxylin and eosin; MT, Masson trichrome.
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FIG. 2. Immunohistochemical staining for cannabinoid receptor expression, CB1, CB2, GPR55, GPR18, TRPV1,
PPARa, and PPARc in OA articular cartilage and bone together with rabbit IgG control. CB, cannabinoid; GPR, G-
protein-coupled receptor; OA, osteoarthritis; PPAR, peroxisome proliferator-activated receptors; TRPV, transient
receptor potential vanilloid.
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FIG. 3. Quantitative analysis of immunopositivity of cannabinoid receptors in each zone of articular cartilage
and bone. (A) CB1 immunopositivity. (B) CB2 immunopositivity. (C) GPR55 immunopositivity. (D) GPR18
immunopositivity. (E) TRPV1 immunopositivity. (F) PPARa immunopositivity. (G) PPARc immunopositivity.
*p < 0.05, **p < 0.01, ***p < 0.001. DZ, deep zone; MZ, middle zone; SZ, superﬁcial zone.
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FIG. 4. Quantitative analysis of immunopositivity of cannabinoid receptors in the deep zone of OA articular
cartilage. (A) CB1 immunopositivity. (B) CB2 immunopositivity. (C) GPR55 immunopositivity. (D) GPR18
immunopositivity. (E) TRPV1 immunopositivity. (F) PPARa immunopositivity. (G) PPARc immunopositivity. (H)
Correlation of grade of cartilage degeneration and GPR18 immunopositivity. *p < 0.05. ID, intermediate
degeneration; LD, low degeneration; ND, nondegenerate; SD, severe degeneration.
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FIG. 5. Quantitative analysis of immunopositivity of cannabinoid receptors in osteocytes. (A) CB1
immunopositivity. (B) CB2 immunopositivity. (C) GPR55 immunopositivity. (D) GPR18 immunopositivity.
(E) TRPV1 immunopositivity. (F) PPARa immunopositivity. (G) PPARc immunopositivity. (H) Immunopositivity
within osteocytes for PPARc within the underlying bone correlation with grade of cartilage degradation for
tissue sample. *p < 0.05.
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surface zones are lost during degeneration and thus
may impact on the responsiveness of cells.
Other workers have demonstrated expression of CB1
and CB2 by bovine articular chondrocytes,20 synovia of
patients with OA and RA,30 and human chondrocytes
and ﬁbroblast-like synoviocytes.19,39 Here, we demon-
strate CB1 and CB2 localization within the cell mem-
brane and cytoplasm of chondrocytes in all zones of
cartilage and in the underlying osteocytes. Although
CB1 and CB2 are cell membrane receptors, they have
been shown to redistribute and trafﬁc to different cel-
lular components following ligand binding.53 In mice,
deﬁciency of CB2 receptors has been associated with
more rapid development of OA during aging and in
mice with DMM-induced OA, suggesting the impor-
tance of this receptor in chondroprotection.8
GPR55 has previously been shown to be expressed
by both normal and OA chondrocytes,19 which agrees
with the ﬁndings of this study, where we also demon-
strated no signiﬁcant difference between grade of
degeneration and GPR55 expression. GPR18 is primar-
ily expressed in testes and spleen and in addition is
expressed in other tissues and cells involved in endo-
crine and immune functions.54 We have shown, for
the ﬁrst time, that GPR18 is expressed by chondrocytes
in OA cartilage. Immunopositivity for GRP18 was
highest within the middle and deep zone than in the su-
perﬁcial zone of the cartilage, although the percentage
of cells with immunopositivity decreased in the deep
zone of the cartilage with increasing grade of degener-
ation. These ﬁndings indicate that GPR18 may play a
role in the pathogenesis of OA and may have different
functions in the middle and deep zones of the cartilage,
as chondrocytes in different zones are known to ex-
press different molecules and display distinct func-
tions.2 This novel ﬁnding of GPR18 in cartilage and
bone suggests a role in cartilage and bone metabolism,
which requires further investigation.
TRPV1 acts as an endogenous cannabinoid recep-
tor for AEA and has also been shown to bind phytocan-
nabinoids including CBD.17,18 TRPV1 is mainly
expressed by nociceptive neurons and is activated by
noxious heat and capsaicin.55,56 TRPV1 expression
has been associated with arthritic pain in animal mod-
els and is increased in knee innervation in a rat OA
model compared to control animals.57 TRPV1 KO
mice have reduced thermal hyperalgesic sensitivity in
an adjuvant-induced arthritis model.58 In humans,
TRPV1 has been shown to be expressed in OA chon-
drocytes at the mRNA level and OA and RA synovial
ﬁbroblasts at the mRNA and protein levels.29,32 Any ef-
fects of chondrocyte TRPV1 stimulation on pain may
be indirect. However, it may be postulated that an in-
crease in TRPV1 expression would be associated with
OA disease progression. Interestingly, in this study, it
was shown that TRPV1 expression was signiﬁcantly
decreased in the deep zone of the cartilage with severe
degeneration compared with cartilage with low degen-
eration. However, a decrease in TRPV1 expression has
been associated with a differentiated phenotype in
human OA chondrocytes cultures,29 suggesting that a
decrease in TRPV1 expression observed in OA carti-
lage may be due to more differentiated chondrocytes
in the deep zone in severe degeneration during OA.59
PPARc immunopositivity increased in chondrocytes
in the superﬁcial zone of cartilage, although this failed
to reach signiﬁcance and immunopositivity was pre-
dominantly nuclear. In agreement with this ﬁnding,
PPARc was previously shown to be mainly expressed
in the superﬁcial zone of human OA cartilage and
PPARc expression has been shown to be nuclear in
rat cartilage.22,23 In animal models of arthritis, the
PPARc agonist pioglitazone reduced the development
and severity of cartilage lesions60,61 and the importance
of PPARc in cartilage development and homeosta-
sis has recently been investigated,44,62 where PPARc
cartilage-speciﬁc KO mice exhibited a spontaneous
OA phenotype.44 Mice displayed histological features
of OA, including cartilage degradation, increased pro-
teoglycan loss, hypocellularity, calciﬁed cartilage, ﬁbril-
lation, synovial inﬂammation, and ﬁbrosis compared
with age-matched controls.44
Similarly, in mice with inducible, cartilage-speciﬁc
PPARc KO with DMM-induced OA, OA development
was accelerated. In addition, increased expression of
catabolic and inﬂammatory markers was observed in
chondrocytes.44 We have shown that there was no sig-
niﬁcant difference in PPARc expression in OA cartilage
compared to grade of degeneration; however, PPARc
was decreased in osteocytes in the underlying bone of
OA cartilage with increasing grade of degeneration.
Cartilage-speciﬁc PPARc-deﬁcient mice displayed
bone defects, including reduced length of long bones,
bone density, and trabecular bone thickness,62 suggest-
ing that PPARc is involved in bone metabolism. PPARc
agonists rosiglitazone and pioglitazone reduced bone
erosions and inﬂammatory bone loss in a collagen-
induced arthritis model,63 and PPARc signaling
pathway genes are upregulated during the osteoblast
mineralization process.64 Although reduced expression
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of PPARc is thought to play a role in the pathogenesis
of OA,22,25,44 its role in bone metabolism during OA re-
mains to be deﬁned.
There was no signiﬁcant difference in PPARa expres-
sion observed between different microscopic grades of
OA cartilage. In agreement with our study, Aﬁf et al.22
showed that PPARa was expressed by human articular
chondrocytes and no differences in expression were ob-
served in different grades of OA.22 In vivo studies have
also demonstrated that PPARa expression levels did
not change during the progression of OA in animal
models.25
We have previously shown that synthetic cannabi-
noid WIN-55 reduces the gene expression of MMP-3
and MMP-13 in OA chondrocytes;9 however, the mech-
anisms by which this occurs are unknown. Here, we
show that in chondrocyte cultures multiple cannabi-
noid receptors are expressed, suggesting that WIN-55
may mediate its effects through one or more of these
receptors.
Conclusions
This study demonstrates that chondrocytes within OA
cartilage and osteocytes within the underlying bone ex-
press a wide range of cannabinoid receptors. However,
cannabinoid receptor expression of CB1, CB2, GPR55,
PPARa, and PPARc in cartilage does not appear to be
associated with grade of degeneration. Changes in
TRPV1 and GPR18 expression were seen in the deep
zone of the cartilage with increasing grade of degener-
ation, although whether these receptors are important
in OA disease mechanisms remains to be deﬁned.
The maintenance of cannabinoid receptor expression
shown in this study during OA suggests that these
cells would remain responsive to cannabinoid receptor-
targeted therapy using selective ligands. It is important
to further identify the role of these receptors within
normal and OA cartilage to elucidate their potential
as possible targets in the treatment of OA.
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AEA¼ arachidonoylethanolamide
CB¼ cannabinoid
CBD¼Cannabidiol
DMM¼ destabilized medial meniscus
GPR¼G-protein-coupled receptor
IL¼ interleukin
IMS¼ industrial methylated spirits
KO¼ knockout
MMPs¼matrix metalloproteinases
OA¼ osteoarthritis
PPAR¼ peroxisome proliferator-activated receptors
RA¼ rheumatoid arthritis
TRPV¼ transient receptor potential vanilloid
TBS¼ Tris buffered saline
WIN-55¼WIN 55, 212-2 mesylate
WT¼wild type
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